Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has provided an update on its outstanding shares as of December 1, 2022. The company reports a total of 80,812,069 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights is 80,969,909, while the exercisable voting rights are noted as 80,951,334. This disclosure aligns with French stock-market regulations and aims to keep the market informed about the company’s capital structure.

Innate Pharma announced three poster presentations at the ESMO Immuno-Oncology Annual Congress on December 8, 2022, in Geneva, Switzerland. The posters include Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, presented by AstraZeneca, and preclinical data supporting its Phase 2 development in non-small cell lung cancer. The IPH5301, a CD73-blocking antibody, will also be showcased along with the trial design.

Innate Pharma reported a cash position of €151.4 million as of September 30, 2022, ensuring a cash runway into H2 2024. The company showcased preliminary data from the Phase 2 TELLOMAK trial of lacutamab, highlighting a clinical activity with a global objective response rate (ORR) of 28.6% in mycosis fungoides. Additionally, lacutamab's ongoing Phase 2 data in Sézary syndrome is set to be presented at the ASH 2022 Annual Congress on December 10. Revenues for the first nine months of 2022 reached €44.3 million, compared to €10.3 million for the same period in 2021.

Innate Pharma announced a conference call on November 14, 2022, at 2 p.m. CET / 8 a.m. ET, to discuss third-quarter business progress. Key speakers include CEO Mondher Mahjoubi and other executives. The call will be available via webcast and telephone registration, providing access for questions. Innate Pharma, focused on oncology, utilizes therapeutic antibodies to enhance cancer treatment outcomes. It has a broad pipeline and alliances with several major biopharmaceutical companies.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) is set to present preliminary results from the TELLOMAK Phase 2 trial evaluating lacutamab for advanced Sézary syndrome at the ASH Annual Meeting, December 10-13, 2022, in New Orleans. Highlights include an oral presentation by CSO Eric Vivier on the ANKET™ platform and two poster presentations by partner Sanofi on SAR'579/IPH6101 and SAR'514/IPH6401. Lacutamab, a first-in-class anti-KIR3DL2 antibody, has received EMA PRIME designation and FDA Fast Track status for treatment in Sézary syndrome patients.

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) has announced that its senior management team will participate in two upcoming investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15-16, 2022, in New York, while the Evercore ISI HealthConX Conference will take place from November 29 to December 1, 2022, virtually. Innate Pharma focuses on oncology, developing therapeutic antibodies that utilize the immune system to enhance cancer treatment outcomes. It has a robust pipeline and strategic collaborations with major biopharmaceutical companies.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has released its 2023 financial calendar, scheduling key financial reports throughout the year. Important dates include:

• March 23, 2023: Publication of 2022 financial statements
• May 10, 2023: 1Q2023 revenue announcement
• September 14, 2023: Half-year financial statements
• November 14, 2023: 3Q2023 revenue release

All reports will be made public before market open CET. For more details about the company and its activities, visit the website.

Innate Pharma has presented preliminary data at the EORTC CLTG annual meeting, demonstrating promising clinical responses from its anti-KIR3DL2 antibody, lacutamab, in patients with mycosis fungoides (MF) who have undergone previous systemic therapies. The Phase 2 TELLOMAK trial revealed a global objective response rate of 28.6% in KIR3DL2-expressing patients, with a favorable safety profile. The company anticipates sharing final data from this trial in 2023, alongside ongoing studies for other lymphomas.

Innate Pharma reported consolidated financial results for the first half of 2022, showcasing a net income of €6.3 million compared to a net loss of €23.7 million in the same period last year. Revenue surged to €45.6 million, primarily driven by milestone payments and collaborations with AstraZeneca and Sanofi. Notably, the company advanced the anti-CD39 monoclonal antibody IPH5201 into Phase 2 trials and received a €3 million milestone for IPH6401/sar514. With a strong cash position of €158.2 million, Innate is well-funded through H2 2024.